Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | +9,900.00% | 0.00% | -99.76% |
Apr. 26 | Motion for Asset Sale Approved for Biocept, Inc. | CI |
Apr. 02 | Motion for Asset Sale Approved for Biocept, Inc. | CI |
Financials (USD)
Sales 2021 | 61.25M | Sales 2022 | 25.86M | Capitalization | 9.04M |
---|---|---|---|---|---|
Net income 2021 | -2M | Net income 2022 | -32M | EV / Sales 2021 | 0.73 x |
Net cash position 2021 | 16.19M | Net cash position 2022 | 788K | EV / Sales 2022 | 0.32 x |
P/E ratio 2021 |
-18.9
x | P/E ratio 2022 |
-0.28
x | Employees | 50 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 100% |
Latest transcript on Biocept, Inc.
1 day | +9,900.00% | ||
6 months | -99.80% | ||
Current year | -99.76% |
Managers | Title | Age | Since |
---|---|---|---|
Barbara Blouw
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Nathaniel Sweed
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Operating Officer | 60 | 22-03-07 |
1st Jan change | Capi. | |
---|---|---|
-99.76% | 262 | |
-5.86% | 12.09B | |
-3.26% | 8.21B | |
+5.47% | 5.74B | |
+29.63% | 5.64B | |
-9.05% | 4.16B | |
-58.10% | 2.88B | |
+11.87% | 2.69B | |
-5.08% | 2.33B | |
+24.06% | 2.17B |
- Stock Market
- Equities
- BIOCQ Stock